Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121221 | 0.91 | KDM4E (0.52) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL7929527 | 0.90 | HTT (0.56) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL257828 | 0.84 | HPGD (0.53) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL7928370 | 0.84 | HPGD (0.60) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL7931144 | 0.84 | HTT (0.54) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL13642366 | 0.83 | KMT2A (0.50) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL27717344 | 0.83 | KMT2A (0.50) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL4573266 | 0.83 | KDM4E (0.58) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL3182217 | 0.83 | KDM4E (0.59) | HPGDKDM4ETDP1KMT2AMEN1 | |
| SCHEMBL1778262 | 0.83 | KDM4E (0.52) | HPGDKDM4ETDP1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-7459567-B2 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| WO-2006088694-A1 | SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS | WYETH (US) | 2006-08-24 | — | — | WO | disclosed |
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | WYETH (US) | 2006-08-17 | — | — | US | disclosed |
| EP-1140896-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | Takeda Chemical Industries, Ltd. (JP) | 2001-10-10 | — | — | EP | disclosed |
| US-6235771-B1 | AIDS THERPAY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| WO-2000037455-A1 | BENZOTHIEPIN-ANILIDE DERIVATIVES, THEIR PRODUCTION AND THEIR USE FOR ANTAGONIZING CCR-5 | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183792-A1 | Substituted thienyl and furyl acylguanidines and methods of their use as beta-secretase modulators | BACE1, BACE2, PSEN1 | HPGD 1692/4885KDM4E 1194/4885TDP1 399/4885 |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | PAK4, PAK5, PAK1 | HPGD 2381/4885KDM4E 611/4885TDP1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.